RespireRx Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, … Read more
RespireRx Pharmaceuticals Inc (RSPI) - Total Assets
Latest total assets as of September 2023: $108.66K USD
Based on the latest financial reports, RespireRx Pharmaceuticals Inc (RSPI) holds total assets worth $108.66K USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
RespireRx Pharmaceuticals Inc - Total Assets Trend (1988–2022)
This chart illustrates how RespireRx Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
RespireRx Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
RespireRx Pharmaceuticals Inc's total assets of $108.66K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1988–2022)
This chart illustrates how RespireRx Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RespireRx Pharmaceuticals Inc's current assets represent 100.0% of total assets in 2022, an increase from 78.9% in 1988.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2022, down from 45.8% in 1988.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1988.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
RespireRx Pharmaceuticals Inc Competitors by Total Assets
Key competitors of RespireRx Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
RespireRx Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - RespireRx Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - RespireRx Pharmaceuticals Inc is currently not profitable relative to its asset base.
RespireRx Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.00 | 0.02 |
| Quick Ratio | 0.01 | 0.00 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-11.95 Million | $ -11.39 Million | $ -5.74 Million |
RespireRx Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between RespireRx Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 35.95 |
| Asset Growth Rate (YoY) | -89.1% |
| Total Assets | $22.78K |
| Market Capitalization | $819.01K USD |
Valuation Analysis
Premium Asset Valuation: The market values RespireRx Pharmaceuticals Inc's assets at a significant premium ( 35.95x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: RespireRx Pharmaceuticals Inc's assets decreased by 89.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for RespireRx Pharmaceuticals Inc (1988–2022)
The table below shows the annual total assets of RespireRx Pharmaceuticals Inc from 1988 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $22.78K | -89.09% |
| 2021-12-31 | $208.74K | +145.32% |
| 2020-12-31 | $85.09K | +87.71% |
| 2019-12-31 | $45.33K | -63.50% |
| 2018-12-31 | $124.19K | -36.24% |
| 2017-12-31 | $194.77K | -16.71% |
| 2016-12-31 | $233.85K | +60.34% |
| 2015-12-31 | $145.84K | -63.57% |
| 2014-12-31 | $400.31K | +669.82% |
| 2013-12-31 | $52.00K | -73.87% |
| 2012-12-31 | $199.00K | -89.07% |
| 2011-12-31 | $1.82 Million | -48.96% |
| 2010-12-31 | $3.57 Million | +405.29% |
| 2009-12-31 | $705.98K | -86.30% |
| 2008-12-31 | $5.15 Million | -72.04% |
| 2007-12-31 | $18.43 Million | +76.61% |
| 2006-12-31 | $10.43 Million | -41.99% |
| 2005-12-31 | $17.99 Million | -39.86% |
| 2004-12-31 | $29.91 Million | +1272.68% |
| 2003-12-31 | $2.18 Million | -26.90% |
| 2002-12-31 | $2.98 Million | -46.20% |
| 2001-12-31 | $5.54 Million | 0.00% |
| 2000-12-31 | $5.54 Million | +58.84% |
| 1999-12-31 | $3.49 Million | +125.18% |
| 1998-12-31 | $1.55 Million | -46.12% |
| 1997-12-31 | $2.87 Million | -65.50% |
| 1996-12-31 | $8.33 Million | +70.07% |
| 1995-12-31 | $4.90 Million | 0.00% |
| 1994-12-31 | $4.90 Million | -52.88% |
| 1993-12-31 | $10.40 Million | -20.06% |
| 1992-12-31 | $13.01 Million | +359.72% |
| 1991-12-31 | $2.83 Million | +59.89% |
| 1990-12-31 | $1.77 Million | -35.64% |
| 1989-12-31 | $2.75 Million | -46.18% |
| 1988-12-31 | $5.11 Million | -- |